GLP1R and diabetes mellitus: Therefore, the generalizability of our findings needs to be confirmed in patients with diabetes who are at lower cardiovascular risk and/or are treated with newly developed glucose lowering drugs such as GLP-1 receptor agonists and SGLT2 inhibitors.